Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
China Pharma Holdings Inc (CPHI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: CPHI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -41.54% | Avg. Invested days 14 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.69M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1055706 | Beta 0.71 | 52 Weeks Range 0.13 - 0.41 | Updated Date 11/21/2024 |
52 Weeks Range 0.13 - 0.41 | Updated Date 11/21/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -70.49% | Operating Margin (TTM) -150.44% |
Management Effectiveness
Return on Assets (TTM) -17.54% | Return on Equity (TTM) -74.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8580989 | Price to Sales(TTM) 0.95 |
Enterprise Value 8580989 | Price to Sales(TTM) 0.95 | ||
Enterprise Value to Revenue 1.55 | Enterprise Value to EBITDA -225.89 | Shares Outstanding 19253400 | Shares Floating 7948937 |
Shares Outstanding 19253400 | Shares Floating 7948937 | ||
Percent Insiders 51.28 | Percent Institutions 0.21 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
China Pharma Holdings Inc
Company Overview
History and Background
China Pharma Holdings, Inc. was founded in 1993. It's a specialty pharmaceutical company in China focusing on research, development, manufacture, and commercialization of pharmaceutical products.
Core Business Areas
- Pharmaceutical Products: Development, manufacture, and commercialization of prescription and OTC pharmaceutical products in therapeutic areas such as cardiovascular, cerebrovascular, and respiratory.
Leadership and Structure
Information on China Pharma Holdings' leadership team and organizational structure is limited in readily available public sources.
Top Products and Market Share
Key Offerings
- Product Name 1: Cardiovascular drugs: Specific names are unavailable; market share data not publicly available. Competitors are other pharmaceutical companies manufacturing cardiovascular medications in China.
- Product Name 2: Cerebrovascular drugs: Specific names are unavailable; market share data not publicly available. Competitors are other pharmaceutical companies manufacturing cerebrovascular medications in China.
- Product Name 3: Respiratory drugs: Specific names are unavailable; market share data not publicly available. Competitors are other pharmaceutical companies manufacturing respiratory medications in China.
Market Dynamics
Industry Overview
The Chinese pharmaceutical market is large and growing, driven by an aging population, increasing healthcare expenditure, and expanding health insurance coverage. However, it is also highly competitive and regulated.
Positioning
China Pharma Holdings is a smaller player in a large and competitive market. Its competitive advantages are dependent on its product portfolio and distribution network.
Total Addressable Market (TAM)
The Chinese pharmaceutical market is estimated at hundreds of billions of dollars. China Pharma Holdings' TAM is a portion of this, determined by their product focus. Exact figures depend on products and market share in sub-segments
Upturn SWOT Analysis
Strengths
- Established presence in China
- Experience in pharmaceutical development
- Distribution network in China
Weaknesses
- Small market share
- Limited financial resources
- Dependence on regulatory approvals
- Lack of detailed public financial information in English
Opportunities
- Growing Chinese pharmaceutical market
- Increasing demand for healthcare products
- Potential for new product development
- Partnerships with international pharmaceutical companies
Threats
- Intense competition
- Stringent regulations
- Price pressures
- Currency fluctuations
Competitors and Market Share
Key Competitors
- Unable to find information on US ticker symboled competitors for China Pharma Holdings. Competitors reside in China.
Competitive Landscape
China Pharma Holdings faces significant competition in the Chinese pharmaceutical market. Assessing its advantages and disadvantages requires more detailed information on its specific products, market share, and financial performance, which is not publicly available.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Unable to determine historical growth due to limited data.
Future Projections: Unable to provide future projections due to limited analyst coverage.
Recent Initiatives: Information on recent strategic initiatives is limited in readily available public sources.
Summary
China Pharma Holdings is a small player in the competitive Chinese pharmaceutical market. Its strengths lie in its established presence and experience, but it faces challenges due to its limited resources and competitive pressures. Opportunities exist in the growing market, but success depends on navigating regulatory hurdles and securing a larger market share. Due to data limitations, a comprehensive analysis is difficult to perform.
Similar Companies
Sources and Disclaimers
Data Sources:
- Publicly available news articles, company press releases, SEC filings (limited), and general industry reports.
Disclaimers:
The information provided is based on limited publicly available data and may not be entirely accurate or complete. This analysis is not financial advice, and investment decisions should be made based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China Pharma Holdings Inc
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2002-04-17 | President, CEO, Chairman & Interim CFO Ms. Zhilin Li | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 231 | |
Full time employees 231 | |||
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.